A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients with Acute Coronary Syndrome - PLATO
Study identifier:D5130C05262
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a study of PLATelet inhibition and patient Outcomes]
Medical condition
Acute Coronary Syndrome
Phase
Phase 3
Healthy volunteers
No
Study drug
Ticagrelor, Clopidogrel
Sex
All
Actual Enrollment
18624
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Oct 2006
Primary Completion Date: 01 Mar 2009
Study Completion Date: 01 Mar 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Feb 2012 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Clopidogrel Oral treatment | Drug: Clopidogrel Clopidogrel 75 mg once daily dose (ODD) Other Name: Plavix® |
| Experimental: Ticagrelor Oral treatment | Drug: Ticagrelor Ticagrelor (AZD6140) 90 mg twice daily dose (BD) Other Name: AZD6140 |
Contacts
Investigators
Principal Investigator
Robert Harrington
Duke Clinical Research Institute
